- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What Dr Zahra Mahmoudjafari Wishes Payers Knew About CAR T-Cell Therapies
Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, gives her take on what payers should keep in mind when dealing with chimeric antigen receptor (CAR) T-cell therapies.
Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager of hematology, bone marrow therapy, and cellular therapeutics at the University of Kansas Health System, gives her take on what payers should keep in mind when dealing with chimeric antigen receptor (CAR) T-cell therapies.
Transcript
What do you wish that more payers understood about CAR T therapies?
CAR T therapies fall under a new line of care called immune effector cell therapies and they are here to stay. They're very scientifically exciting, but I think operationally and logistically pretty challenging. I think what I would like payers to know is that while they are scientifically very, very exciting, we're still learning a lot about them and we are improving care every single day, whether it's through the different ways we select our patients or how we prioritize care.
And then additionally, I think I'd like payers to know specifically with the CAR T therapies at this time point, time is of the essence and these patients' [cases] are relapsed and refractory. And right now, our CAR T products are manufactured over the course of 3 to 4 to even 5 weeks and many times those patients don't have that kind of time. So, any delay is very impactful in their care.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment
November 9th 2023Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
Read More
Innovation in Value-Based Care Requires More Data, Patient-Centered Thinking
November 9th 2023In a panel discussion at the 2023 Patient-Centered Oncology Care® meeting held in Nashville, Tennessee, experts discussed the Enhancing Oncology Model and themes in the movement toward value-based care in oncology.
Read More
